New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases.
Acta Neurochir (Wien)
; 164(6): 1623-1626, 2022 06.
Article
de En
| MEDLINE
| ID: mdl-34825968
ABSTRACT
New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs, as a previously unreported finding. Both patients were in their 40 s and administered new-generation TKIs without vascular risk factors. New-generation TKIs for CML can cause major cerebrovascular stenosis without any symptoms. Examining the neck and intracranial arteries using magnetic resonance angiography and carotid ultrasonography may prevent future cerebral infarctions associated with these TKIs.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Leucémie myéloïde chronique BCR-ABL positive
/
Inhibiteurs de protéines kinases
Type d'étude:
Risk_factors_studies
Limites:
Humans
Langue:
En
Journal:
Acta Neurochir (Wien)
Année:
2022
Type de document:
Article
Pays d'affiliation:
Japon